
## Darintr Sosothikul

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7706428/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Complicated bleeding challenge and intraoperative safety strategies in a case of hemophilia a with rhabdomyosarcoma. Pediatric Hematology and Oncology, 2022, , 1-6.	0.3	2
2	Dermatologic manifestations in pediatric patients after liver and HSCT: A 20â€year retrospective cohort study. Pediatric Transplantation, 2021, 25, e13916.	0.5	2
3	Systemic Coagulopathy in Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962098762.	0.7	20
4	Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110089.	0.7	16
5	The Pattern of Microorganisms and Drug Susceptibility in Pediatric Oncologic Patients with Febrile Neutropenia. Journal of Pathogens, 2021, 2021, 1-9.	0.9	4
6	<b><i>MYH9</i> disorder</b> : <b>Identification and a novel mutation in patients with macrothrombocytopenia</b> . Pediatric Blood and Cancer, 2021, 68, e29055.	0.8	1
7	A Study to Assess and Improve Adherence to Iron Chelation Therapy in Transfusion-Dependent Thalassemia Patients. Hemoglobin, 2021, 45, 171-174.	0.4	3
8	A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Advances, 2021, 5, 2925-2934.	2.5	12
9	A Pharmacokinetic Study of Native E.coli Asparaginase for Acute Lymphoblastic Leukemia Treated with ThaiPOG Protocol. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3309-3315.	0.5	0
10	lmmunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial. Blood, 2021, 138, 3184-3184.	0.6	2
11	A novel deletion in the fibrinogen beta chain (FCB) gene causing hypofibrinogenemia. Thrombosis Research, 2020, 186, 26-29.	0.8	1
12	Prophylactic vs episodic treatment to prevent bleeds and preserve joint function in Thai children with moderate and severe haemophilia A. Haemophilia, 2020, 26, e18-e20.	1.0	2
13	Pediatric primary central nervous system tumors registry in Thailand under National Health Security Office schemes. Journal of Neuro-Oncology, 2020, 149, 141-151.	1.4	10
14	Comparison of different prophylactic regimens for Thai children with moderate and severe haemophilia A. Haemophilia, 2020, 26, e211-e213.	1.0	1
15	Clinical and molecular characteristics of Thai patients with ELANE-related neutropaenia. Journal of Clinical Pathology, 2020, , jclinpath-2020-207139.	1.0	3
16	Imaging findings of spontaneous thymic hemorrhage in infancy: Case report and literature review. The Asean Journal of Radiology, 2020, , 44-57.	0.1	0
17	Predictive Factors of Severe Adverse Events in Pediatric Oncologic Patients with Febrile Neutropenia. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3487-3492.	0.5	2
18	Whole exome sequencing for diagnosis of hereditary thrombocytopenia. Medicine (United States), 2020, 99, e23275.	0.4	7

DARINTR SOSOTHIKUL

#	Article	IF	CITATIONS
19	Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961986691.	0.7	2
20	Study of Bernard–Soulier Syndrome Megakaryocytes and Platelets Using Patient-Derived Induced Pluripotent Stem Cells. Thrombosis and Haemostasis, 2019, 119, 1461-1470.	1.8	6
21	Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study. BMC Cancer, 2019, 19, 961.	1.1	10
22	Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia. Blood, 2019, 134, 2036-2045.	0.6	33
23	Appropriateness of pediatric CT utilization in clinical practice. The Asean Journal of Radiology, 2019, , 4-17.	0.1	0
24	DEV-16. TREATMENT OF CENTRAL NERVOUS SYSTEM ATYPICAL TERATOID/RHABDOID TUMOR WITH VDC/ICE PROTOCOL, SURGERY AND CRANIOSPINAL IRRADIATION. Neuro-Oncology, 2018, 20, i48-i48.	0.6	0
25	Efficacy and safety of lowâ€dose prophylaxis of highly purified plasmaâ€derived factor VIII concentrate produced by the National Blood Centre, Thai Red Cross Society. Haemophilia, 2018, 24, e387-e390.	1.0	7
26	BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma. Human Pathology, 2017, 69, 118-122.	1.1	31
27	Exome sequencing for simultaneous mutation screening in children with hemophagocytic lymphohistiocytosis. International Journal of Hematology, 2017, 106, 282-290.	0.7	21
28	Novel mutations in Thai patients with glanzmann thrombasthenia. European Journal of Haematology, 2017, 99, 520-524.	1.1	3
29	Adrenal insufficiency in nonâ€transfusionâ€dependent αâ€thalassemia. Pediatrics International, 2017, 59, 1135-1139.	0.2	0
30	Testicular function in patients with regular blood transfusion for thalassemia major. Asian Biomedicine, 2017, 9, 185-191.	0.2	5
31	NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica, 2016, 101, e24-e26.	1.7	76
32	Adaptive immune defects in a patient with leukocyte adhesion deficiency type <scp>III</scp> with a novel mutation in <i><scp>FERMT</scp>3</i> . Pediatric Allergy and Immunology, 2016, 27, 214-217.	1.1	18
33	Redefining clinical risk classification in children with precursor B cell acute lymphoblastic leukemia using pre-treatment absolute lymphocyte count. Leukemia and Lymphoma, 2016, 57, 953-956.	0.6	1
34	Reference values for thrombotic markers in children. Blood Coagulation and Fibrinolysis, 2012, 23, 208-211.	0.5	21
35	Pediatric REFERENCE Values for Molecular Markers in Hemostasis. Journal of Pediatric Hematology/Oncology, 2007, 29, 19-22.	0.3	43
36	Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thrombosis and Haemostasis, 2007, 97, 627-34.	1.8	50

#	Article	IF	CITATIONS
37	Changes in ADAMTS 13 Activity and Von Willebrand Factor Parameters during Acute Dengue Infection Blood, 2006, 108, 1492-1492.	0.6	8